Related Experiment Video

Updated: Nov 7, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.0K

Prevalence of thrombotic complications in children with SARS-CoV-2

David Aguilera-Alonso1,2, Sara Murias3, Amelia Martínez-de-Azagra Garde4

  • 1Pediatric Infectious Diseases Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain david.aguilera@salud.madrid.org.

Archives of Disease in Childhood
|May 1, 2021
PubMed

Insights

Thrombosis is rare in children with SARS-CoV-2 (COVID-19), affecting 0.7% of infected children. Adolescents and those with prior risk factors may benefit from anticoagulant prophylaxis.

Area of Science:

  • Pediatric infectious diseases
  • Hematology
  • Cardiovascular complications

Background:

  • Limited data exists on thrombosis in pediatric SARS-CoV-2 (COVID-19) cases.
  • Thrombotic events are a serious concern in viral infections.

Purpose of the Study:

  • To determine the prevalence of thrombotic complications in children with SARS-CoV-2.
  • To describe the characteristics of pediatric patients experiencing thrombosis post-SARS-CoV-2 infection.
  • To review existing literature on pediatric thrombosis related to SARS-CoV-2.

Main Methods:

  • Multicenter national cohort study involving 537 pediatric patients with SARS-CoV-2 across 49 hospitals.
  • Analysis of patient characteristics, thrombotic events, and D-dimer levels.
  • Literature review of published pediatric cases of SARS-CoV-2-associated thrombosis.

Main Results:

  • Four out of 537 infected children (0.7%) developed thrombotic complications.
  • Prevalence was 1.1% among hospitalized pediatric patients.
  • Three of the four affected patients were adolescent girls; two had pre-existing thrombotic risk factors.
  • D-dimer levels were not sufficiently specific for predicting thrombosis in this cohort.

Conclusions:

  • Thrombotic complications, though uncommon, occur in children with SARS-CoV-2 (COVID-19).
  • Adolescent age and pre-existing thrombotic risk factors may warrant consideration for anticoagulant prophylaxis.
  • Further research is needed to refine risk stratification and management strategies for pediatric thrombosis in COVID-19.

Keywords:
Covid-19epidemiology

More Related Videos

In Vitro Thrombosis Test for Ventricular Assist Devices09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

919
Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.5K

Related Concept Videos

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
96
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
90
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
222
Prevalence and Incidence01:08

Prevalence and Incidence

In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
1.1K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
89
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
56